# FDA 483 - Southwest Fertility Center - April 14, 2026

Source: https://www.keypedia.com/records/483/southwest-fertility-center/f24f07b3-16f8-4b7a-8ac8-f25aacf04a82

> FDA 483 for Southwest Fertility Center on April 14, 2026. Product: biologics. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: Southwest Fertility Center
- Inspection Date: 2026-04-14
- Product Type: biologics
- Office Name: Denver District Office
- Summary: An FDA inspection of Southwest Fertility Center in Phoenix, AZ, identified multiple deficiencies related to donor eligibility for Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps). The firm failed to ensure donors were properly tested and screened for communicable diseases, maintained incomplete and inaccurate donor records, and lacked proper documentation of eligibility determinations. These issues indicate significant non-compliance in ensuring the safety and suitability of HCT/P donors.

## Related Documents

- [483 - 2021-03-16](https://www.keypedia.com/records/483/southwest-fertility-center/2716aed2-5114-4aaa-b5d8-46aee7a24f11)

## Related Officers

- [Garrad R. Poole](https://www.keypedia.com/people/garrad-r-poole/7fc97953-367e-459b-905d-25efe6ec39d2)

Company: https://www.keypedia.com/companies/southwest-fertility-center/88230ca1-5d96-4b57-8c8c-84495eb723f6

Office: https://www.keypedia.com/offices/denver-district-office/93b79063-390c-4759-af6c-5da7e388face